IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix
IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix
Read moreTue, 12th May 2020 08:58
IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreAngle's Parsortix Able To Predict Patients' Response To Treatment
Read moreIN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix
Read more(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.
Read moreAngle Progresses On Parsortix And De Novo Clearance From US Regulator
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreIN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board
Read moreAngle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Read moreUK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE
Read more(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Read moreUK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial
Read more(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
Read moreAngle Parsortix Test Used To Help Discover Brain Metastasis
Read more